CY1124859T1 - Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων - Google Patents

Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων

Info

Publication number
CY1124859T1
CY1124859T1 CY20211100850T CY211100850T CY1124859T1 CY 1124859 T1 CY1124859 T1 CY 1124859T1 CY 20211100850 T CY20211100850 T CY 20211100850T CY 211100850 T CY211100850 T CY 211100850T CY 1124859 T1 CY1124859 T1 CY 1124859T1
Authority
CY
Cyprus
Prior art keywords
diabetes
treatment
related diseases
homodimer
peptide
Prior art date
Application number
CY20211100850T
Other languages
English (en)
Inventor
Arpi Rogers
Original Assignee
Arpi Rogers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arpi Rogers filed Critical Arpi Rogers
Publication of CY1124859T1 publication Critical patent/CY1124859T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η εφεύρεση αφορά θεραπευτικά πεπτίδια και χρήσεις αυτών. Συγκεκριμένα η εφεύρεση αφορά συνδεδεμένα μέσω δισουλφιδικών δεσμών ομοδιμερή χρήσιμα στη θεραπεία ή την πρόληψη νόσων και καταστάσεων σε θηλαστικά υποκείμενα (όπως διαβήτης) μέσω διαβλενογοννικής χορήγησης.
CY20211100850T 2014-11-18 2021-09-30 Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων CY1124859T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1420445.7A GB2532426B (en) 2014-11-18 2014-11-18 Therapeutic homodimer and uses thereof
PCT/EP2015/076712 WO2016079066A1 (en) 2014-11-18 2015-11-16 Therapeutic homodimer and uses thereof

Publications (1)

Publication Number Publication Date
CY1124859T1 true CY1124859T1 (el) 2022-11-25

Family

ID=52248504

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100850T CY1124859T1 (el) 2014-11-18 2021-09-30 Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων

Country Status (20)

Country Link
US (2) US20180015136A1 (el)
EP (1) EP3220939B1 (el)
JP (1) JP6693969B2 (el)
KR (1) KR20170083064A (el)
CN (1) CN107206048B (el)
AU (1) AU2015348673B2 (el)
BR (1) BR112017010346A2 (el)
CA (1) CA2967140C (el)
CY (1) CY1124859T1 (el)
DK (1) DK3220939T3 (el)
EA (1) EA034876B1 (el)
ES (1) ES2886001T3 (el)
GB (1) GB2532426B (el)
HK (1) HK1223287A1 (el)
IL (1) IL252349B (el)
MA (1) MA40969A (el)
MX (1) MX2017006278A (el)
SG (1) SG11201703757PA (el)
WO (1) WO2016079066A1 (el)
ZA (1) ZA201703580B (el)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516527D0 (en) * 2005-08-11 2005-09-21 Arpi Matossian Rogers Peptides
EA015629B1 (ru) * 2005-08-11 2011-10-31 Арпи Матоссиан-Роджерс Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний

Also Published As

Publication number Publication date
CA2967140C (en) 2021-09-21
JP2018500386A (ja) 2018-01-11
US20210060118A1 (en) 2021-03-04
GB2532426B (en) 2016-11-02
EA034876B1 (ru) 2020-04-01
ZA201703580B (en) 2018-08-29
EA201791103A1 (ru) 2017-09-29
AU2015348673A1 (en) 2017-06-01
CA2967140A1 (en) 2016-05-26
US20180015136A1 (en) 2018-01-18
GB2532426A (en) 2016-05-25
NZ731655A (en) 2020-09-25
AU2015348673B2 (en) 2019-01-03
KR20170083064A (ko) 2017-07-17
JP6693969B2 (ja) 2020-05-13
SG11201703757PA (en) 2017-06-29
EP3220939B1 (en) 2021-06-30
CN107206048B (zh) 2021-02-26
ES2886001T3 (es) 2021-12-16
MX2017006278A (es) 2017-10-24
IL252349A0 (en) 2017-07-31
BR112017010346A2 (pt) 2018-05-15
CN107206048A (zh) 2017-09-26
MA40969A (fr) 2021-04-28
WO2016079066A1 (en) 2016-05-26
IL252349B (en) 2022-02-01
GB201420445D0 (en) 2014-12-31
DK3220939T3 (da) 2021-08-30
EP3220939A1 (en) 2017-09-27
HK1223287A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1126074T1 (el) Περιοχες gla ως παραγοντες στοχευσης
CO2018006050A2 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591839A1 (ru) Терапевтические пептиды
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CO7400885A2 (es) Análogos de glucagón
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201692109A1 (ru) Варианты антител к фактору d и их применение
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112017012381A2 (pt) imunoterapia para doença angiogênica